WAVEMAN · COMPANY

KARD · Kardigan, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

KARD

Name: Kardigan, Inc. (KARD) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Kardigan, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002123613

CLUSTER · 3 INSIDERSACTIVIST 13D☆ WATCH

INSIDER NET · 180D

$90.0M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$90.0M over 180 days

+$90.0M over 90 days · +$90.0M of it by a 10%+ holder

more than 99% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

69 funds added or opened last quarter

more than 53% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

1.7% of shares outstanding short · 6.7 days to cover · settled 2026-07-31

below 67% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

3 insiders independently bought a net $90.0M — no planned sales are queued against it.

69 funds added or opened positions in the latest 13F quarter, of 69 holders.

ARCH Venture Fund XIII, L.P. disclosed a 5%+ stake (16.2%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -5.2%

-5.2%12M

INSIDER BUY13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

3 insiders reported buying shares.

The record shows a net $90.0M bought by insiders over 180 days, 69 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Kardigan, Inc. insiders bought a net $90.0M of stock across 3 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

HRTG PV, L.P.

—

BUY

2026-06-22

3,125,000.0

$50.0M

BERNS PAUL L

Director

BUY

2026-06-22

1,250,000.0

$20.0M

NELSEN ROBERT

Director

BUY

2026-06-22

1,250,000.0

$20.0M

3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

HRTG GPE, LLC

16,917,034.0 sh

$403.5M

FMR LLC

8,909,066.0 sh

$212.5M

PERCEPTIVE ADVISORS LLC

8,200,662.0 sh

$195.6M

Capital Research Global Investors

3,598,942.0 sh

$85.8M

JPMORGAN CHASE & CO

1,790,734.0 sh

$46.4M

5%+ owners

13D = intent to influence · 13G = passive

ARCH Venture Fund XIII, L.P.

ACTIVIST 13D · 2026-06-29

16.2%

ARCH Venture Partners XIII, L.P.

ACTIVIST 13D · 2026-06-29

16.2%

ARCH Venture Partners XIII, LLC

ACTIVIST 13D · 2026-06-29

16.2%

Robert Nelsen

ACTIVIST 13D · 2026-06-29

16.2%

Keith Crandell

ACTIVIST 13D · 2026-06-29

16.2%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Clinical pipeline

ClinicalTrials.gov · 5 registered trials, 4 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

1 ACTIVE

Phase 3

1 ACTIVE

Multi-phase

2 ACTIVE

What changed recently

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Ge

2026-09-03 · Not Yet Recruiting → Recruiting

Phase 3

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED